IOVANCE BIOTHERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Debt Securities, Available-for-sale, Amortized Cost of $248.11 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $248.11M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $196.05M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $194.31M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $192.43M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $248.11M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $196.05M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $194.31M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $192.43M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $250.11M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $312.20M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $269.40M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $335.75M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $245.76M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $267.76M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $198.99M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $215.99M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $196.87M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $368.41M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $373.37M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $329.23M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $412.25M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $491.55M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $579.62M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $596.11M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $619.86M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $472.11M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $611.81M 10-K · filed 2022-02-24 | $563.95M 10-K · filed 2021-02-25 |
| 2020-09-30 | $646.13M 10-Q · filed 2020-11-05 | |
| 2019-12-31 | $292.42M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |